APA (7th ed.) Citation

Moore, K. N., Birrer, M. J., Marsters, J., Wang, Y., Choi, Y., Royer-Joo, S., . . . Liu, J. F. (2020). Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology, 158(3), 631. https://doi.org/10.1016/j.ygyno.2020.05.039

Chicago Style (17th ed.) Citation

Moore, Kathleen N., et al. "Phase 1b Study of Anti-NaPi2b Antibody-drug Conjugate Lifastuzumab Vedotin (DNIB0600A) in Patients with Platinum-sensitive Recurrent Ovarian Cancer." Gynecologic Oncology 158, no. 3 (2020): 631. https://doi.org/10.1016/j.ygyno.2020.05.039.

MLA (9th ed.) Citation

Moore, Kathleen N., et al. "Phase 1b Study of Anti-NaPi2b Antibody-drug Conjugate Lifastuzumab Vedotin (DNIB0600A) in Patients with Platinum-sensitive Recurrent Ovarian Cancer." Gynecologic Oncology, vol. 158, no. 3, 2020, p. 631, https://doi.org/10.1016/j.ygyno.2020.05.039.